stanolone benzoate: RN given refers to (5alpha,17beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 13987 |
| CHEBI ID | 34979 |
| SCHEMBL ID | 3366936 |
| MeSH ID | M0119611 |
| Synonym |
|---|
| unii-t74307g2d9 |
| 4-09-00-00464 (beilstein handbook reference) |
| t74307g2d9 , |
| 5alpha-androstan-3-one, 17beta-hydroxy-, benzoate |
| androstan-3-one, 17-(benzoyloxy)-, (5alpha,17beta)- |
| (5-alpha,17-beta)-17-(benzoyloxy)androstan-3-one |
| 5-alpha-androstan-3-one, 17-beta-hydroxy-, benzoate |
| 5alpha-dihydrotestosterone benzoate |
| 5-alpha-17-beta-hydroxyandrostan-3-one benzoate |
| brn 3122672 |
| nsc 69549 |
| einecs 213-891-8 |
| androstan-3-one, 17-(benzoyloxy)-, (5-alpha,17-beta)- |
| 5-alpha-dihydrotestosterone benzoate |
| nsc69549 |
| androstanolone benzoate |
| dihydrotestosterone benzoate |
| sarcosan |
| hermalone |
| nsc-69549 |
| 1057-07-4 |
| 5.alpha.-androstan-3-one, benzoate |
| 5.alpha.-dihydrotestosterone benzoate |
| stanolone benzoate |
| [(5s,8r,9s,10s,13s,14s,17s)-10,13-dimethyl-3-oxo-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl] benzoate |
| SCHEMBL3366936 |
| androstanolone 17-benzoate |
| vetranal |
| AKOS015889514 |
| 5.alpha.-androstan-3-one, 17.beta.-hydroxy-, benzoate |
| CHEBI:34979 |
| androstan-3-one, 17-(benzoyloxy)-, (5.alpha.,17.beta.)- |
| (5.alpha.,17.beta.)-3-oxoandrostan-17-yl benzoate |
| ZGDZDAPCWHIIKB-LVYWIKMTSA-N |
| androstanolone benzoate;dihydrotestosterone benzoate;dhtb |
| DTXSID0036502 |
| androstanolone 17-benzoate, vetranal(tm), analytical standard |
| 5alpha-androstan-17beta-ol-3-one benzoate |
| 1,6,7,12-tetrachloroperylenetetracarboxylic aciddianhydride |
| Q27116348 |
| HY-128698 |
| (8r,9s,10s,13s,14s,17s)-10,13-dimethyl-3-oxohexadecahydro-1h-cyclopenta[a]phenanthren-17-yl benzoate |
| dhtb |
| CS-0098596 |
| PD126040 |
| Class | Description |
|---|---|
| steroid ester | |
| 3-oxo-5alpha-steroid | A 3-oxo steroid that has alpha configuration at position 5. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (50.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.44) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||